Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Open in Screener

KYTX

Kyverna Therapeutics Inc.

May 15 • 02:58PM ET

16.05

Dollar change +0.55
Percentage change 3.53	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: VXF SCHA VTI ITOT SCHB IBRN BMED

Index	-	P/E	-	EPS (ttm)	-	Insider Own	29.61%	Shs Outstand	43.12M	Perf Week	26.75%
Market Cap	691.92M	Forward P/E	-	EPS next Y	-4.12	Insider Trans	19.27%	Shs Float	30.35M	Perf Month	-28.46%
Income	-	PEG	-	EPS next Q	-0.77	Inst Own	13.28%	Short Float	6.40%	Perf Quarter	-46.32%
Sales	-	P/S	-	EPS this Y	96.06%	Inst Trans	-	Short Ratio	4.95	Perf Half Y	-
Book/sh	8.37	P/B	1.92	EPS next Y	-16.62%	ROA	-	Short Interest	1.94M	Perf Year	-
Cash/sh	8.58	P/C	1.87	EPS next 5Y	-	ROE	-	52W Range	12.26 - 35.06	Perf YTD	-46.51%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-54.23%	Beta	-
Dividend TTM	-	Quick Ratio	17.17	Sales past 5Y	-37.90%	Gross Margin	-	52W Low	30.88%	ATR (14)	1.56
Dividend Ex-Date	-	Current Ratio	17.17	EPS Y/Y TTM	-	Oper. Margin	-	RSI (14)	43.95	Volatility	10.65% 9.90%
Employees	96	Debt/Eq	0.03	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	42.75
Option/Short	Yes / Yes	LT Debt/Eq	0.02	EPS Q/Q	-	Payout	-	Rel Volume	0.99	Prev Close	15.50
Sales Surprise	-	EPS Surprise	-33.33%	Sales Q/Q	-	Earnings	May 14 AMC	Avg Volume	392.30K	Price	16.05
SMA20	-0.17%	SMA50	-26.29%	SMA200	-31.71%	Trades		Volume	329,198	Change	3.53%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-04-24	Initiated	Wells Fargo	Overweight	$44
Mar-04-24	Initiated	Morgan Stanley	Overweight	$40
Mar-04-24	Initiated	Leerink Partners	Outperform	$48
Mar-04-24	Initiated	JP Morgan	Overweight	$39

May-14-24 10:54PM	KYTX Stock Earnings: Kyverna Therapeutics Misses EPS for Q1 2024 (InvestorPlace) +5.95%
04:05PM	Kyverna Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results (PR Newswire)
Apr-11-24 05:01PM	Kyverna Therapeutics to attend the 2024 American Academy of Neurology (AAN) Annual Meeting in Denver, CO, With Data on KYV-101 in the Treatment of Patients with Neurological Autoimmune Diseases (PR Newswire)
Mar-29-24 02:59PM	First-in-Disease Use of Kyverna Therapeutics' KYV-101 in Patients With Progressive Multiple Sclerosis Published in Med (PR Newswire)
Mar-26-24 04:05PM	Kyverna Therapeutics Provides Business Update and Reports Full Year 2023 Financial Results (PR Newswire) +6.97%
07:00AM	Loading…
Mar-14-24 07:00AM	Why That Hot Biotech IPO Could Be a Winner (The Wall Street Journal)
Mar-07-24 07:26PM	Kyverna Therapeutics and Stanford University Agree to Evaluate KYV-101 in Patients with Non-Relapsing and Progressive Forms of Multiple Sclerosis (PR Newswire)
06:14PM	How Kyverna is positioned for success on autoimmune therapy: CEO (Yahoo Finance Video)
Feb-12-24 04:39PM	Kyverna Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (PR Newswire)
Feb-07-24 10:29PM	Kyverna Therapeutics Announces Pricing of Upsized Initial Public Offering (PR Newswire)

Kyverna Therapeutics, Inc. is a cell therapy clinical-stage biotechnology company. It develops treatments and potential cures for serious autoimmune diseases. The company was founded in June 2018 and is headquartered in Emeryville, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
GILEAD SCIENCES, INC.	10% Owner	Feb 12 '24	Buy	22.00	910,000	20,020,000	4,126,119	Feb 13 05:48 PM
Northpond Ventures III GP, LLC	Former 10% Owner	Feb 12 '24	Buy	22.00	450,000	9,900,000	450,000	Feb 12 05:51 PM
Bain Capital Life Sciences Inv	10% Owner	Feb 12 '24	Buy	22.00	450,000	9,900,000	3,163,868	Feb 14 05:26 PM
Vida Ventures, LLC	10% Owner	Feb 12 '24	Buy	22.00	253,136	5,568,992	252,553	Feb 14 07:04 PM

Open in Screener

URGN

UroGen Pharma Ltd

May 15 • 02:58PM ET

13.65

Dollar change +0.68
Percentage change 5.24	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: IWM IBB IWO IZRL VTWO IWC IWN ITEQ VFMO VTWG

Index	RUT	P/E	-	EPS (ttm)	-3.39	Insider Own	15.70%	Shs Outstand	32.49M	Perf Week	2.86%
Market Cap	493.17M	Forward P/E	-	EPS next Y	-2.90	Insider Trans	-0.37%	Shs Float	30.46M	Perf Month	-5.80%
Income	-104.32M	PEG	-	EPS next Q	-0.85	Inst Own	74.01%	Short Float	14.55%	Perf Quarter	-28.98%
Sales	84.30M	P/S	5.85	EPS this Y	-1.31%	Inst Trans	-0.53%	Short Ratio	12.69	Perf Half Y	16.07%
Book/sh	-1.11	P/B	-	EPS next Y	19.29%	ROA	-66.54%	Short Interest	4.43M	Perf Year	15.58%
Cash/sh	4.56	P/C	2.99	EPS next 5Y	-	ROE	-	52W Range	8.69 - 24.13	Perf YTD	-9.00%
Dividend Est.	-	P/FCF	-	EPS past 5Y	5.89%	ROI	-179.57%	52W High	-43.43%	Beta	1.09
Dividend TTM	-	Quick Ratio	7.20	Sales past 5Y	13144.25%	Gross Margin	89.53%	52W Low	57.08%	ATR (14)	0.94
Dividend Ex-Date	-	Current Ratio	7.47	EPS Y/Y TTM	29.75%	Oper. Margin	-82.12%	RSI (14)	47.24	Volatility	9.08% 6.31%
Employees	201	Debt/Eq	-	Sales Y/Y TTM	24.00%	Profit Margin	-123.74%	Recom	1.40	Target Price	38.50
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	25.47%	Payout	-	Rel Volume	1.56	Prev Close	12.97
Sales Surprise	-12.20%	EPS Surprise	-11.93%	Sales Q/Q	9.24%	Earnings	May 13 BMO	Avg Volume	349.30K	Price	13.65
SMA20	-1.25%	SMA50	-6.91%	SMA200	-10.84%	Trades		Volume	462,822	Change	5.24%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-08-23	Downgrade	Jefferies	Buy → Hold	$35 → $10
Apr-27-22	Initiated	Berenberg	Buy	$20
Apr-16-20	Reiterated	H.C. Wainwright	Buy	$53 → $57
Apr-13-20	Reiterated	H.C. Wainwright	Buy	$75 → $53
Jan-09-20	Initiated	National Securities	Neutral	$37
May-30-19	Initiated	JP Morgan	Neutral
May-29-19	Initiated	Goldman	Neutral
Jan-29-19	Initiated	H.C. Wainwright	Buy	$82
Nov-08-18	Resumed	Jefferies	Buy
Apr-04-18	Upgrade	Raymond James	Mkt Perform → Outperform
Jan-02-18	Initiated	Ladenburg Thalmann	Buy	$50
Nov-15-17	Reiterated	Oppenheimer	Outperform	$32 → $51
Nov-15-17	Downgrade	Raymond James	Outperform → Mkt Perform

Show Previous Ratings

May-14-24 08:20AM	UroGen Pharma Ltd. (NASDAQ:URGN) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-13-24 12:53PM	URGN Stock Earnings: UroGen Pharma Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
09:32AM	UroGen Pharma Ltd (URGN) Q1 2024 Earnings: Misses EPS Estimates, Revenue Slightly Above Expectations (GuruFocus.com)
08:00AM	UroGen Pharma Announces Date for ENVISION Data, New Long-Term Jelmyto Durability Data, and Reports 2024 First Quarter Financial Results and Business Highlights (Business Wire)
May-07-24 08:00AM	UroGen Pharma to Participate at Upcoming Investor Conferences (Business Wire)
12:20PM	Loading…
May-05-24 12:20PM	New Real-World Retrospective Analysis Presented at AUA 2024 Reports 86% Recurrence-Free Survival (RFS) at 24 Months with JELMYTO Across All Studied Patient and Disease Characteristics in Cohort of Responders to Induction Therapy (Business Wire)
May-04-24 03:20PM	UroGen Announces Results from ATLAS Showing Robust UGN-102 Durability of Response in New and Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer at AUA 2024 (Business Wire)
11:50AM	New Real-World Study on Retrograde Instillation of JELMYTO for Treatment of Low-Grade Upper Tract Urothelial Cancer Reports Similar Complete Response Rate and Lower Stricture Rate Compared to OLYMPUS Pivotal Trial (Business Wire)
May-03-24 08:00AM	UroGen Pharma to Report 2024 First Quarter Financial Results on Monday, May 13, 2024 (Business Wire)
Apr-17-24 12:02PM	UroGen Announces New Data Presentations at the American Urological Association 2024 Annual Meeting Highlighting Clinical Benefits of Our Portfolio for Urothelial Cancers (Business Wire)
Apr-15-24 08:00AM	UroGen Announces FDA Acceptance of Investigational New Drug Application for UGN-103, a Next Generation Mitomycin-Based Formulation for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (Business Wire)
Apr-03-24 08:00AM	UroGen Pharma Files Patent Infringement Action Against Teva Pharmaceuticals (Business Wire)
Mar-15-24 10:30AM	UroGen Pharma Ltd. (NASDAQ:URGN) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-14-24 12:53PM	URGN Stock Earnings: UroGen Pharma Misses EPS, Beats Revenue for Q4 2023 (InvestorPlace) -17.97%
09:32AM	UroGen Pharma Ltd (URGN) Reports Solid JELMYTO Growth Amidst Financial Challenges (GuruFocus.com)
09:10AM	Loading…
09:10AM	Urogen Pharma (URGN) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
08:00AM	UroGen Pharma Delivers Double Digit JELMYTO Growth and Prepares for the Next Phase of the Company with on Track Rolling Submission of UGN-102 (Business Wire)
Mar-08-24 08:00AM	UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-04-24 08:00AM	UroGen Pharma to Report Fourth Quarter and Full-Year 2023 Financial Results on Thursday, March 14, 2024 (Business Wire)
Feb-26-24 08:00AM	UroGen Pharma to Present at TD Cowen 44th Annual Health Care Conference (Business Wire) +5.09%
Feb-01-24 08:00AM	UroGen Pharma to Participate at Upcoming Investor Conferences (Business Wire)
Jan-24-24 08:00AM	UroGen Initiates Submission of a Rolling NDA to the FDA for UGN-102 (Business Wire)
Jan-17-24 08:00AM	UroGen Secures Exclusive License from medac GmbH to Develop a Next-Generation Novel Mitomycin-Based Formulation for Urothelial Cancers (Business Wire) +6.27%
Jan-11-24 08:00AM	UroGen Pharma to Participate in the B. Riley Healthcare Conference (Business Wire)
Dec-08-23 04:00PM	UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-15-23 01:50PM	UroGen Pharma Ltd. (NASDAQ:URGN) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-14-23 12:19PM	UroGen Pharma Ltd (URGN) Reports Growth in Q3 Revenue and Progress in Clinical Trials (GuruFocus.com)
08:00AM	UroGen Pharma Reports Third Quarter 2023 Financial Results (Business Wire)
Nov-13-23 08:00AM	UroGen will Present Scientific Advances in Bladder Cancer at the Annual Meeting of the Society of Urologic Oncology (Business Wire)
Nov-07-23 08:00AM	UroGen Pharma to Report Third Quarter 2023 Financial Results on Tuesday, November 14, 2023 (Business Wire)
08:00AM	Loading…
Oct-03-23 08:00AM	Following Pre-NDA Meeting with the FDA, UroGen Announces Rolling NDA Submission for UGN-102 to Begin January 2024 (Business Wire)
Sep-11-23 07:00AM	Eledon Pharmaceuticals Appoints Industry Veteran James Robinson to its Board of Directors (GlobeNewswire)
Sep-08-23 08:00AM	UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Aug-31-23 08:00AM	UroGen Pharma to Present at Upcoming Investor Conferences (Business Wire)
Aug-18-23 01:40PM	UroGen Pharma (URGN) Stock Surges 89% in a Month: Here's Why (Zacks)
Aug-17-23 07:00AM	New Treatment for Bladder Cancer Offers This Biotech a Second Chance (The Wall Street Journal) -14.16%
Aug-12-23 09:18AM	UroGen Pharma Ltd. (NASDAQ:URGN) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-10-23 09:55AM	Wall Street Analysts Think Urogen Pharma (URGN) Could Surge 89.61%: Read This Before Placing a Bet (Zacks)
09:15AM	Urogen Pharma (URGN) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
08:00AM	UroGen Pharma Reports Record JELMYTO Quarterly Sales and Recent Corporate Developments (Business Wire)
Aug-08-23 08:00AM	The Journal of Urology Publishes Peer-Reviewed Article Highlighting UGN-102 Data in Non-Surgical Treatment for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (Business Wire)
Aug-02-23 05:00PM	UroGen Pharma to Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023 (Business Wire) -6.45%
Aug-01-23 10:05AM	Opportunities Outweigh Risks: Oppenheimer Sees at Least 60% Gains in These 2 Stocks (TipRanks) -6.28%
Jul-31-23 08:00AM	UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-28-23 01:41PM	Why Shares of UroGen Pharma Jumped Friday (Motley Fool) +26.38%
Jul-27-23 09:55AM	UroGen Announces $120 Million Private Placement of Ordinary Shares (Business Wire) +98.56%
09:50AM	UGN-102, in Development as the Potential First Non-Surgical Therapy for LG-IR-NMIBC, Met Primary Endpoints in Both Phase 3 ATLAS and ENVISION Clinical Trials (Business Wire)
Jul-25-23 04:10PM	UroGen Pharma Announces the Appointment of James Robinson to its Board of Directors (Business Wire)
Jul-10-23 08:00AM	Retrospective Study Finds JELMYTO® Use Effective Following Partial Ablation or Biopsy in Larger Volume Low-Grade Upper Tract Urothelial Tumors that Impede Kidney Preservation (Business Wire) -5.28%
Jul-06-23 08:00AM	UroGen Pharma to Host UGN-102 Data Event on July 27, 2023 (Business Wire) +5.08%
Jun-20-23 08:00AM	Retrospective Study Reveals Lower Stricture Rate and Comparable Oncological Outcomes with Antegrade Administration of JELMYTO® Versus Retrograde Administration (Business Wire)
Jun-09-23 08:00AM	UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +5.33%
Jun-02-23 08:00AM	UroGen Pharma to Present at Upcoming Investor Conferences (Business Wire)
May-22-23 01:18PM	With 58% institutional ownership, UroGen Pharma Ltd. (NASDAQ:URGN) is a favorite amongst the big guns (Simply Wall St.)
May-16-23 12:13PM	UroGen Pharma Ltd. (NASDAQ:URGN) Q1 2023 Earnings Call Transcript (Insider Monkey)
May-11-23 09:15AM	Urogen Pharma (URGN) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +8.00%
08:00AM	UroGen Pharma Meets Revenue Goal, Reports First Quarter 2023 Financial Results and Recent Corporate Developments (Business Wire)
May-04-23 08:00AM	UroGen Pharma to Report 2023 First Quarter Financial Results on Thursday, May 11, 2023 (Business Wire)
May-02-23 10:02AM	Earnings Preview: Urogen Pharma (URGN) Q1 Earnings Expected to Decline (Zacks) -8.61%
May-01-23 02:00PM	First Study to Evaluate JELMYTO® Use Post-Complete Endoscopic Ablation Reports 69% of Patients were Disease Free at the Time of First Endoscopic Evaluation (Business Wire) +23.30%
Apr-30-23 08:00AM	New Retrospective Study Presented at AUA 2023 Provides Evidence of Similar Outcomes Utilizing JELMYTO® in the Treatment of UTUC of the Ureter and Renal Pelvis (Business Wire)
Apr-25-23 08:00AM	UroGen Pharma to Present at H.C. Wainwright BioConnect Conference (Business Wire)
Apr-18-23 12:16PM	UroGen Pharma Ltd.'s (NASDAQ:URGN) Prospects Need A Boost To Lift Shares (Simply Wall St.)
Mar-18-23 02:06AM	UroGen Pharma Ltd. (NASDAQ:URGN) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-16-23 09:15AM	Urogen Pharma (URGN) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
08:00AM	UroGen Pharma Reports Highest Revenue Quarter and Significant Full Year 2022 Growth and Recent Corporate Developments (Business Wire)
Mar-09-23 04:00PM	UroGen Pharma to Report Fourth Quarter and Full-Year 2022 Financial Results on Thursday, March 16, 2023 (Business Wire)
Mar-06-23 08:00AM	UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-01-23 04:00PM	UroGen Pharma to Present at Upcoming Investor Conferences (Business Wire)
Feb-27-23 08:15AM	Axsome Therapeutics (AXSM) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
Feb-15-23 09:06AM	Investigational Therapy UGN-102 May Be Delivered at Home for the Treatment of Bladder Cancer (Business Wire)
Feb-06-23 05:33AM	UroGen Pharma Ltd. (NASDAQ:URGN) Is Expected To Breakeven In The Near Future (Simply Wall St.)
Jan-11-23 08:00AM	Results of the First Post-Commercial Utilization Review of JELMYTO® Provide New Evidence that Reinforces its Efficacy and Safety in Patients with Low-Grade Upper Tract Urothelial Cancer (Business Wire)
Jan-09-23 12:19PM	The past five years for UroGen Pharma (NASDAQ:URGN) investors has not been profitable (Simply Wall St.)
Dec-19-22 08:00AM	UroGen Completes Enrollment of Its Phase 3 Clinical Trial for UGN-102 in Development for Low-Grade, Intermediate-Risk, Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC) (Business Wire)
Dec-13-22 12:13PM	With 57% institutional ownership, UroGen Pharma Ltd. (NASDAQ:URGN) is a favorite amongst the big guns (Simply Wall St.)
Dec-09-22 08:00AM	UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Dec-02-22 12:00PM	UroGen Announces New Data from the OPTIMA II Study that Show Median Durability of Response of 24.4 Months for UGN-102, an Investigational Non-Surgical Chemoablative Treatment for Low-Grade, Intermediate-Risk Non-Muscle Invasive Bladder Cancer (Business Wire)
Dec-01-22 07:00PM	UroGen Announces New Data from the OLYMPUS Trial that Shows Median Durability of Response of 28.9 Months for JELMYTO®, the Only Non-Surgical, Chemoablative Treatment for Adults with Low-Grade Upper Tract Urothelial Cancer (Business Wire)
Nov-21-22 04:00PM	UroGen Pharma to Present at Evercore ISI 5th Annual Virtual HealthCONx Conference (Business Wire) -7.51%
Nov-16-22 11:24AM	Some Analysts Just Cut Their UroGen Pharma Ltd. (NASDAQ:URGN) Estimates (Simply Wall St.)
Nov-14-22 08:00AM	UroGen Highlights New Real-World Safety Data Published in The British Journal of Urology International That Showed a Low Rate of Ureteral Stenosis When Antegrade Administration of JELMYTO® was Used in Patients with Upper Tract Urothelial Carcinoma (Business Wire)
Nov-12-22 07:33AM	UroGen Pharma Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag (Simply Wall St.)
Nov-10-22 09:15AM	Urogen Pharma (URGN) Reports Q3 Loss, Lags Revenue Estimates (Zacks) -16.32%
08:00AM	UroGen Pharma Reports Third Quarter 2022 Financial Results and Recent Corporate Developments (Business Wire)
Nov-09-22 08:00AM	UroGen Announces the Appointment of Dan Wildman to the UroGen Pharma Board of Directors (Business Wire) -7.66%
Nov-03-22 08:00AM	UroGen Pharma to Report Third Quarter 2022 Financial Results on Thursday, November 10, 2022 (Business Wire)
Oct-12-22 04:29AM	Urogen Pharma (URGN) Moves 10.3% Higher: Will This Strength Last? (Zacks) +6.22%
Oct-11-22 11:54AM	10 Best Immunotherapy Stocks To Buy Now (Insider Monkey)
08:00AM	UroGen Pharma to Host Thought Leader Webinar on UGN-102 and Non-Muscle Invasive Bladder Cancers (Business Wire)
Sep-28-22 08:00AM	FDA Authorizes an Extension of the In-Use Period for UroGen Pharmas JELMYTO® Admixture to 96 Hours Following Reconstitution (Business Wire) +7.58%
Sep-12-22 08:00AM	UroGen Announces the Appointment of Dr. Leana S. Wen to the UroGen Pharma Board of Directors (Business Wire) +5.70%
Sep-09-22 08:00AM	UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-07-22 04:00PM	UroGen Pharma Announces Upcoming 2022 Conferences (Business Wire)
Aug-11-22 09:15AM	Urogen Pharma (URGN) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -6.51%
08:00AM	UroGen Pharma Reports Second Quarter 2022 Financial Results and Recent Corporate Developments (Business Wire)
Jul-27-22 08:00AM	UroGen Pharma to Report Second Quarter 2022 Financial Results on Thursday, August 11, 2022 (Business Wire)
Jul-24-22 09:56AM	UroGen Pharma (NASDAQ:URGN) shareholders have endured a 73% loss from investing in the stock three years ago (Simply Wall St.)
Jul-12-22 09:05AM	10 Micro-Cap Stocks To Buy According To Cathie Wood (Insider Monkey)
Jun-09-22 09:07AM	Do Institutions Own UroGen Pharma Ltd. (NASDAQ:URGN) Shares? (Simply Wall St.)

UroGen Pharma Ltd. is a biopharmaceutical company, which engages in developing and commercializing innovative solutions that treat urothelial and specialty cancers. It also focuses on developing RTGel reverse-thermal hydrogel, a proprietary sustained release and hydrogel-based platform technology. The company was founded by Asher Holzer in 2004 and is headquartered in Princeton, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Schoenberg Mark	Chief Medical Officer	Mar 18 '24	Sale	14.05	12,000	168,600	139,437	Mar 20 04:38 PM
Smith Jason Drew	General Counsel	Jan 31 '24	Sale	15.74	4,993	78,590	18,824	Feb 02 07:12 PM
Schoenberg Mark	Chief Medical Officer	Jan 31 '24	Sale	15.74	3,789	59,639	149,423	Feb 02 07:07 PM
Smith Jason Drew	General Counsel	Aug 31 '23	Sale	18.01	3,800	68,438	18,407	Sep 05 04:28 PM

Open in Screener

CDNA

Caredx Inc

May 15 • 02:58PM ET

14.92

Dollar change -0.32
Percentage change -2.10	%

Healthcare • Diagnostics & Research • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: ARKG IWM VTI VXF IWN VB IBB LABU DFAT VBK

Index	RUT	P/E	-	EPS (ttm)	-3.43	Insider Own	6.50%	Shs Outstand	51.50M	Perf Week	46.56%
Market Cap	777.03M	Forward P/E	-	EPS next Y	-1.29	Insider Trans	0.00%	Shs Float	48.70M	Perf Month	90.06%
Income	-183.19M	PEG	-	EPS next Q	-0.42	Inst Own	98.47%	Short Float	10.56%	Perf Quarter	79.98%
Sales	275.11M	P/S	2.82	EPS this Y	57.19%	Inst Trans	-1.83%	Short Ratio	5.82	Perf Half Y	88.38%
Book/sh	4.95	P/B	3.02	EPS next Y	14.59%	ROA	-37.36%	Short Interest	5.14M	Perf Year	78.90%
Cash/sh	4.15	P/C	3.60	EPS next 5Y	20.00%	ROE	-54.18%	52W Range	4.80 - 15.91	Perf YTD	24.33%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-21.96%	ROI	-64.71%	52W High	-6.22%	Beta	1.81
Dividend TTM	-	Quick Ratio	4.03	Sales past 5Y	33.42%	Gross Margin	62.03%	52W Low	210.83%	ATR (14)	1.00
Dividend Ex-Date	-	Current Ratio	4.32	EPS Y/Y TTM	-127.34%	Oper. Margin	-35.90%	RSI (14)	78.26	Volatility	10.40% 7.77%
Employees	643	Debt/Eq	0.13	Sales Y/Y TTM	-13.93%	Profit Margin	-66.59%	Recom	1.86	Target Price	14.75
Option/Short	Yes / Yes	LT Debt/Eq	0.10	EPS Q/Q	27.20%	Payout	-	Rel Volume	0.53	Prev Close	15.24
Sales Surprise	14.13%	EPS Surprise	32.42%	Sales Q/Q	-6.75%	Earnings	May 09 AMC	Avg Volume	883.55K	Price	14.92
SMA20	52.84%	SMA50	50.08%	SMA200	63.59%	Trades		Volume	395,085	Change	-2.10%

Date	Action	Analyst	Rating Change	Price Target Change
May-13-24	Downgrade	Raymond James	Outperform → Mkt Perform
May-01-24	Upgrade	Craig Hallum	Hold → Buy	$15
Nov-09-23	Upgrade	Stephens	Equal-Weight → Overweight	$10
Aug-15-23	Upgrade	Raymond James	Mkt Perform → Outperform	$12
May-11-23	Downgrade	BTIG Research	Buy → Neutral
Mar-07-23	Downgrade	Stephens	Overweight → Equal-Weight	$19 → $9
Mar-03-23	Downgrade	Raymond James	Strong Buy → Mkt Perform
Mar-03-23	Downgrade	Craig Hallum	Buy → Hold	$26 → $9
Apr-25-22	Initiated	Stephens	Overweight	$50
Jul-20-21	Resumed	BTIG Research	Buy	$115
Jun-03-21	Initiated	Goldman	Buy	$95
Feb-26-21	Downgrade	H.C. Wainwright	Buy → Neutral
Oct-30-20	Reiterated	H.C. Wainwright	Buy	$47 → $55
Oct-08-20	Reiterated	H.C. Wainwright	Buy	$45 → $47
Oct-02-20	Reiterated	H.C. Wainwright	Buy	$40 → $45
Aug-05-20	Reiterated	H.C. Wainwright	Buy	$37 → $40
Jun-26-20	Initiated	BTIG Research	Buy	$40
Jun-19-20	Reiterated	H.C. Wainwright	Buy	$40 → $37
Oct-01-19	Resumed	Craig Hallum	Buy	$48
May-09-19	Upgrade	H.C. Wainwright	Neutral → Buy	$30 → $43

Show Previous Ratings

May-14-24 07:17AM	--Raymond James Downgrades CareDx to Market Perform From Outperform (MT Newswires)
May-13-24 10:12AM	Stephens Adjusts Price Target on CareDx to $18 From $15, Maintains Overweight Rating (MT Newswires)
May-10-24 02:26PM	CareDx Shares Rise After Q1 Results Beat Estimates (MT Newswires) +34.09%
02:21PM	CareDx Reports Mixed Q1 2024 Results; Raises Annual Revenue Guidance (GuruFocus.com)
11:46AM	CareDx, Inc (NASDAQ:CDNA) Q1 2024 Earnings Call Transcript (Insider Monkey)
07:00PM	Loading…
May-09-24 07:00PM	CareDx (CDNA) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks) +8.64%
05:32PM	CareDx: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	CareDx Reports First Quarter 2024 Results (Business Wire)
May-07-24 09:15AM	CareDx (CDNA) Q1 Earnings Preview: What You Should Know Beyond the Headline Estimates (Zacks)
May-03-24 04:10PM	CareDx Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Apr-29-24 04:05PM	CareDx to Report First Quarter 2024 Financial Results (Business Wire) +8.47%
Apr-19-24 04:05PM	CareDx Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Apr-18-24 03:47AM	CareDx (CDNA) Moves 5.5% Higher: Will This Strength Last? (Zacks)
Apr-16-24 04:02PM	CareDx Appoints John W. Hanna as its New President and Chief Executive Officer (Business Wire)
Apr-09-24 07:00AM	CareDx and Collaborators Present Latest Cardiothoracic Advancements at the 2024 International Society for Heart and Lung Transplantation Meeting (Business Wire)
08:40AM	Loading…
Apr-01-24 08:40AM	How CareDx (CDNA) Stock Stands Out in a Strong Industry (Zacks)
Mar-11-24 04:10PM	CareDx Appoints Bryan Riggsbee to Its Board of Directors (Business Wire)
Feb-29-24 10:43AM	CareDx, Inc (NASDAQ:CDNA) Q4 2023 Earnings Call Transcript (Insider Monkey) +9.47%
06:59AM	Q4 2023 CareDx Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-28-24 07:00PM	CareDx (CDNA) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
05:28PM	CareDx: Q4 Earnings Snapshot (Associated Press Finance)
04:57PM	CareDx Inc (CDNA) Surpasses Revenue Expectations Despite Net Loss Expansion in 2023 (GuruFocus.com)
04:05PM	CareDx Announces Fourth Quarter and Full Year 2023 Financial Results (Business Wire)
Feb-27-24 04:05PM	CareDx to Participate in the Raymond James & Associates 45th Annual Institutional Investors Conference (Business Wire) +6.39%
Feb-26-24 09:15AM	Unlocking Q4 Potential of CareDx (CDNA): Exploring Wall Street Estimates for Key Metrics (Zacks) +7.86%
Feb-21-24 04:05PM	CareDx to Report Fourth Quarter and Full Year 2023 Financial Results (Business Wire)
07:00AM	CareDx Showcases Digital Solutions and Pipeline in Cellular Transplant and Therapy Monitoring at the 2024 Tandem Meetings (Business Wire)
Jan-26-24 09:45PM	CareDx Issues Statement in Patent Infringement Case (Business Wire) -17.32%
Jan-11-24 04:05PM	CareDx Adds to AlloSure Kidney and HeartCare Utility and Clinical Data at 2024 American Society of Transplant Surgeons Winter Symposium (Business Wire) -7.24%
Jan-09-24 07:00AM	CareDx Reports Preliminary Revenue Results for Fourth Quarter and Full Year 2023 (Business Wire)
07:00AM	Loading…
Dec-19-23 07:00AM	CareDx Joins Forces with the National Foundation for Transplants to Improve Post-Transplant Medication Adherence (Business Wire) +13.81%
Dec-08-23 09:55AM	How Much Upside is Left in CareDx (CDNA)? Wall Street Analysts Think 26.72% (Zacks)
Nov-22-23 09:55AM	Can CareDx (CDNA) Climb 29.79% to Reach the Level Wall Street Analysts Expect? (Zacks)
Nov-10-23 10:15AM	CareDx, Inc (NASDAQ:CDNA) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-08-23 05:02PM	CareDx: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	CareDx Reports Third Quarter 2023 Results (Business Wire)
Nov-06-23 07:38AM	CareDx (CDNA) Surges 16.6%: Is This an Indication of Further Gains? (Zacks)
Nov-02-23 04:05PM	CareDx to Report Third Quarter 2023 Financial Results (Business Wire) +9.98%
Nov-01-23 04:02PM	CareDx Announces CEO Transition (Business Wire)
Oct-17-23 07:00AM	CareDx Presents New Data at the American Society for Histocompatibility and Immunogenetics Annual Meeting (Business Wire)
Oct-03-23 07:12PM	Market Today: Tech Stocks Under Pressure, House Ousts McCarthy, and FTC Accuses Amazon of Price ... (GuruFocus.com)
06:00PM	CareDx Issues Statement on Supreme Court Decision Regarding Stanford-Licensed Patents (Business Wire)
04:43PM	Supreme Court Denies CareDx Request for Appeal in Patent Case with Natera (Business Wire)
Oct-02-23 11:06AM	US Supreme Court rebuffs CareDx patent lawsuit over organ-rejection tests (Reuters)
Sep-19-23 07:00AM	CareDx To Present at the 2023 Cantor Global Healthcare Conference (Business Wire)
Sep-14-23 02:00AM	CareDx Advances Global Transplant Patient Care at ESOT Congress 2023 (Business Wire)
Aug-31-23 07:00AM	CareDx To Present at the H.C. Wainwright 25th Annual Global Investment Conference (Business Wire)
Aug-17-23 07:00AM	CareDx Hosts Second Annual MEET Digital Health User Conference to Showcase Latest Innovations to Enhance Transplant Patient Care (Business Wire)
Aug-15-23 09:59AM	Redfin upgraded, CSSE downgraded: Wall Street's top analyst calls (The Fly)
Aug-11-23 07:00AM	CareDx Comments on Issuance of Proposed LCD for Molecular Testing for Solid Allograft Rejection (Business Wire) -8.06%
Aug-09-23 09:30AM	Compared to Estimates, CareDx (CDNA) Q2 Earnings: A Look at Key Metrics (Zacks) -11.23%
Aug-08-23 06:05PM	CareDx (CDNA) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
05:02PM	CareDx: Q2 Earnings Snapshot (AP Finance)
04:05PM	CareDx Reports Second Quarter 2023 Results (Business Wire)
Aug-07-23 11:08AM	CareDx Announces District Court Judge Bars Natera from Falsely Advertising and Overstating the Scientific Performance of its Prospera Transplant Test (Business Wire)
Aug-03-23 07:00AM	CareDx to Report Second Quarter 2023 Financial Results (Business Wire)
Aug-02-23 07:00AM	CareDxs HeartCare Multimodality Service Receives Medicare Coverage for Heart Transplant Surveillance (Business Wire) +7.34%
Jul-25-23 07:00AM	CareDx Acquires MediGO, an Organ Transplant Supply Chain and Logistics Company (Business Wire) +5.76%
Jul-17-23 11:42PM	CareDx Applauds District Court Decision to Uphold Jury Verdict that Natera Falsely Advertised its Prospera Transplant Test (Business Wire)
Jul-11-23 07:00AM	CareDxs AlloSure Lung dd-cfDNA Testing Service Receives Medicare Coverage for Lung Transplant Rejection Monitoring (Business Wire) +6.49%
Jul-10-23 08:44AM	CareDx (CDNA) Soars 20.6%: Is Further Upside Left in the Stock? (Zacks)
Jul-07-23 12:26PM	Why Shares of CareDx Are Jumping Friday (Motley Fool) +20.55%
Jul-05-23 06:08AM	We're Hopeful That CareDx (NASDAQ:CDNA) Will Use Its Cash Wisely (Simply Wall St.)
Jun-01-23 08:00AM	CareDx Demonstrates Innovation Leadership at 2023 Transplant Congress (Business Wire)
07:00AM	CareDx to Participate in Upcoming Investor Conferences (Business Wire)
May-16-23 07:00AM	CareDx Showcases Digital Health Portfolio at 31st Annual UNOS Transplant Management Forum (Business Wire) -6.83%
06:42AM	Should You Exit CareDx (CDNA)? (Insider Monkey)
06:02AM	What Does The Future Hold For CareDx, Inc (NASDAQ:CDNA)? These Analysts Have Been Cutting Their Estimates (Simply Wall St.)
May-11-23 10:13AM	Q1 2023 CareDx Inc Earnings Call (Thomson Reuters StreetEvents)
May-10-23 05:45PM	CareDx (CDNA) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:43PM	CareDx: Q1 Earnings Snapshot (AP Finance)
04:05PM	CareDx Reports First Quarter 2023 Results (Business Wire)
May-08-23 07:01AM	CareDx to Report First Quarter 2023 Financial Results (Business Wire)
Apr-25-23 06:01AM	CareDx Showcases Latest Advances Across AlloSeq Lab Products Portfolio at the 36th European Immunogenetics and Histocompatibility Conference (Business Wire) -5.21%
Apr-19-23 07:01AM	CareDx Showcases Leadership with Over 55 Oral Presentations and Posters at the 43rd Annual Meeting & Scientific Sessions of the International Society for Heart and Lung Transplantation (Business Wire)
Apr-18-23 01:22PM	CareDx, Inc's (NASDAQ:CDNA) Shares Lagging The Industry But So Is The Business (Simply Wall St.)
Apr-06-23 07:01AM	National Kidney Foundation Honors CareDx with Corporate Citizenship Award for its Commitment to the Transplant Community (Business Wire)
Apr-05-23 06:55AM	CareDx and Miromatrix Announce Exclusive Partnership to Advance Research Using Bioengineered Organs for Human Transplantation (Business Wire)
Mar-23-23 07:01AM	CareDx Presents Latest Advancements at 12th Congress of the International Pediatric Transplant Association (Business Wire)
Mar-11-23 02:46AM	CareDx, Inc (NASDAQ:CDNA) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-07-23 07:01AM	The American Society of Transplant Surgeons Position Statement Supports Use of CareDxs AlloSure Kidney for Organ Transplant Surveillance (Business Wire)
Mar-06-23 04:32PM	CareDx Update Regarding Raymond James & Associates Conference (Business Wire) +18.73%
07:01AM	CareDx To Participate in the Raymond James & Associates 44th Annual Institutional Investors Conference (Business Wire)
Mar-03-23 04:01PM	CareDx Earns Stock Downgrade Amid CMS Coverage Cuts Change Thesis (Benzinga) -16.67%
07:01AM	CareDx Comments on MolDX Publication of New Billing and Coding Article (Business Wire)
Mar-01-23 07:01AM	CareDx Key Supporter of the National Kidney Foundations Annual Kidney Patient Summit (Business Wire)
05:19AM	CareDx Full Year 2022 Earnings: In Line With Expectations (Simply Wall St.)
Feb-28-23 09:58AM	Q4 2022 CareDx Inc Earnings Call (Thomson Reuters StreetEvents) +14.34%
Feb-27-23 05:15PM	CareDx (CDNA) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:01PM	CareDx Reports Fourth Quarter and Full Year 2022 Results (Business Wire)
06:28AM	Baron Discovery Fund Believes CareDx (CDNA) Will Reward Investors for Patience (Insider Monkey)
Feb-22-23 07:01AM	CareDx Showcases Clinical Value of Multimodality and AI Innovation at the American Society of Transplantation Cutting Edge of Transplantation Meeting (Business Wire)
Feb-21-23 04:01PM	CareDx to Report Fourth Quarter and Full Year 2022 Financial Results (Business Wire) -13.72%
Feb-20-23 10:00AM	Analysts Estimate Viatris (VTRS) to Report a Decline in Earnings: What to Look Out for (Zacks)
Feb-16-23 10:01AM	Earnings Preview: CareDx (CDNA) Q4 Earnings Expected to Decline (Zacks)
07:01AM	CareDx Showcases Latest Advancements in Cellular Transplant and Therapy Including Specialized Digital Health Solutions at the 2023 Tandem Meetings (Business Wire)
Feb-01-23 09:48AM	Cathie Wood pours millions into these 2 stocks this is what makes them attractive buys (TipRanks)
Jan-27-23 08:30AM	Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought (Motley Fool)
Jan-26-23 08:21AM	CareDx (NASDAQ:CDNA) delivers shareholders splendid 20% CAGR over 5 years, surging 9.8% in the last week alone (Simply Wall St.)
07:01AM	JACC Publication Guides Use of CareDxs HeartCare Transplant Rejection Surveillance in Clinical Practice (Business Wire)

CareDx, Inc. operates as a transplant diagnostics company, which discovers, develops and commercializes diagnostic solutions. Its products include AlloMap, AlloSure and Laboratory products. The company was founded on December 21, 1998 and is headquartered in Brisbane, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Maag Peter	Director	Apr 29 '24	Option Exercise	5.27	13,281	69,991	327,264	May 01 04:38 PM
Seeto Reginald	See Remarks	Oct 02 '23	Sale	6.91	2,818	19,483	479,164	Oct 02 07:53 PM
Seeto Reginald	See Remarks	Sep 05 '23	Sale	9.49	2,819	26,762	481,982	Sep 05 04:03 PM
Seeto Reginald	See Remarks	Aug 14 '23	Sale	8.89	576	5,123	484,801	Aug 14 07:52 PM
Bickerstaff George	Director	Aug 11 '23	Option Exercise	5.09	19,453	99,065	99,721	Aug 11 07:47 PM
Seeto Reginald	See Remarks	Aug 02 '23	Sale	11.35	2,819	31,988	486,051	Aug 02 06:53 PM
Seeto Reginald	See Remarks	Jul 13 '23	Sale	10.33	5,260	54,357	488,870	Jul 13 08:56 PM
Maag Peter	Director	Jul 13 '23	Sale	10.34	5,000	51,680	309,657	Jul 13 08:56 PM
Seeto Reginald	See Remarks	Jul 03 '23	Sale	8.48	2,818	23,901	498,055	Jul 03 05:19 PM
Seeto Reginald	See Remarks	Jun 28 '23	Sale	8.76	14,268	125,016	500,873	Jun 28 08:44 PM
Maag Peter	Director	Jun 28 '23	Sale	8.72	2,432	21,216	313,136	Jun 28 08:43 PM
Seeto Reginald	See Remarks	Jun 02 '23	Sale	8.13	2,819	22,911	532,177	Jun 02 08:08 PM

Open in Screener

NTLA

Intellia Therapeutics Inc

May 15 • 02:58PM ET

26.31

Dollar change +0.58
Percentage change 2.24	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: ARKK VTI VB ARKG IWM VXF VBK IWN IBB SCHA

Index	RUT	P/E	-	EPS (ttm)	-5.37	Insider Own	2.33%	Shs Outstand	96.48M	Perf Week	14.38%
Market Cap	2.54B	Forward P/E	-	EPS next Y	-5.49	Insider Trans	-2.32%	Shs Float	94.22M	Perf Month	20.62%
Income	-485.50M	PEG	-	EPS next Q	-1.21	Inst Own	88.26%	Short Float	16.39%	Perf Quarter	-6.98%
Sales	52.60M	P/S	48.25	EPS this Y	6.38%	Inst Trans	-0.30%	Short Ratio	10.38	Perf Half Y	10.49%
Book/sh	10.76	P/B	2.45	EPS next Y	-8.26%	ROA	-36.27%	Short Interest	15.44M	Perf Year	-42.51%
Cash/sh	8.20	P/C	3.21	EPS next 5Y	30.00%	ROE	-43.60%	52W Range	19.37 - 47.48	Perf YTD	-13.72%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-22.30%	ROI	-43.03%	52W High	-44.59%	Beta	1.88
Dividend TTM	-	Quick Ratio	9.03	Sales past 5Y	12.09%	Gross Margin	82.06%	52W Low	35.81%	ATR (14)	1.37
Dividend Ex-Date	-	Current Ratio	9.03	EPS Y/Y TTM	0.38%	Oper. Margin	-983.45%	RSI (14)	62.94	Volatility	5.66% 5.29%
Employees	526	Debt/Eq	0.11	Sales Y/Y TTM	-1.63%	Profit Margin	-922.94%	Recom	1.54	Target Price	68.17
Option/Short	Yes / Yes	LT Debt/Eq	0.09	EPS Q/Q	4.25%	Payout	-	Rel Volume	0.53	Prev Close	25.73
Sales Surprise	157.37%	EPS Surprise	18.02%	Sales Q/Q	129.53%	Earnings	May 09 BMO	Avg Volume	1.49M	Price	26.31
SMA20	16.01%	SMA50	4.57%	SMA200	-10.66%	Trades		Volume	673,729	Change	2.24%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-23-24	Downgrade	Goldman	Buy → Neutral	$136 → $32
Feb-15-24	Initiated	Wolfe Research	Peer Perform
Apr-13-23	Initiated	Canaccord Genuity	Buy	$66
Mar-21-23	Initiated	Bernstein	Outperform	$54
Mar-14-23	Upgrade	BMO Capital Markets	Market Perform → Outperform	$54 → $57
Feb-01-23	Initiated	Cantor Fitzgerald	Overweight	$67
Jan-24-23	Upgrade	Citigroup	Sell → Neutral	$48 → $39
Jan-19-23	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Oct-11-22	Initiated	Morgan Stanley	Overweight	$84
Sep-21-22	Initiated	JP Morgan	Overweight	$85
Sep-01-22	Initiated	Citigroup	Sell	$50
Jun-17-22	Initiated	BMO Capital Markets	Market Perform	$54
Jun-16-22	Initiated	BofA Securities	Buy	$70
Apr-28-22	Initiated	Credit Suisse	Outperform	$100
Feb-18-22	Initiated	William Blair	Outperform	$144
Feb-07-22	Upgrade	Oppenheimer	Perform → Outperform	$145 → $150
Jan-31-22	Initiated	Cowen	Outperform
Jan-07-22	Initiated	Piper Sandler	Overweight	$171
Oct-05-21	Initiated	Guggenheim	Buy	$170
Sep-24-21	Initiated	Stifel	Buy	$173

Show Previous Ratings

May-14-24 12:46PM	Analyst Report: Intellia Therapeutics, Inc. (Morningstar Research)
09:30AM	Intellia Therapeutics, Inc. (NTLA) Just Overtook the 50-Day Moving Average (Zacks)
May-13-24 02:18PM	15 Best ARK Stocks To Buy Now (Insider Monkey)
May-10-24 03:35PM	Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q1 2024 Earnings Call Transcript (Insider Monkey)
01:16PM	Intellia Therapeutics Q1 2024 Earnings: Aligns with Analyst Projections Amidst Strategic Advances (GuruFocus.com)
11:45AM	Loading…
11:45AM	Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought (Motley Fool)
11:26AM	Intellia's (NTLA) Q1 Earnings & Revenues Beat Estimates (Zacks)
May-09-24 11:53PM	Q1 2024 Intellia Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) +8.09%
11:42AM	Analyst Report: Intellia Therapeutics, Inc. (Morningstar Research)
08:49AM	Intellia Therapeutics' Q1 Net Loss Narrows, Collaboration Revenue Rises (MT Newswires)
08:40AM	Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:30AM	Intellia Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
May-03-24 06:15PM	Why Intellia Therapeutics, Inc. (NTLA) Outpaced the Stock Market Today (Zacks)
02:18PM	Shhh! 3 Secret Gene Editing Stocks Flying Below Wall Street's Radar (InvestorPlace)
May-02-24 07:30AM	Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2024 Earnings and Company Updates (GlobeNewswire)
06:04AM	Loading…
06:04AM	3 Gene Editing Stocks with the Potential to Make You an Overnight Millionaire (InvestorPlace)
Apr-29-24 07:30AM	Intellia Therapeutics to Present Updated Data from Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the EAACI Congress 2024 (GlobeNewswire) +5.88%
Apr-25-24 11:21AM	Intellia (NTLA) to Report Q1 Earnings: What's in the Cards? (Zacks) -5.43%
10:01AM	Earnings Preview: Intellia Therapeutics, Inc. (NTLA) Q1 Earnings Expected to Decline (Zacks)
Apr-14-24 05:55AM	2 Stocks Down 30% to Buy Right Now (Motley Fool)
Apr-12-24 04:50AM	Cathie Wood Goes Bargain Hunting. 2 Stocks She Bought This Week. (Motley Fool)
Apr-09-24 04:50AM	Bull Market and Beyond: 3 Stocks Just Waiting to Soar (Motley Fool)
Mar-28-24 05:55AM	Better Cathie Wood Stock: Moderna vs. Intellia (Motley Fool)
Mar-21-24 05:29PM	Hot Stocks: The 3 Best Opportunities for Investing in Biotech (InvestorPlace)
04:19PM	3 Stocks That Could Be the Next Big Thing in Gene Editing (InvestorPlace)
Mar-19-24 01:06PM	Intellia (NTLA) Begins Dosing in Phase III ATTR Amyloidosis Study (Zacks)
Mar-18-24 07:30AM	Intellia Therapeutics Announces First Patient Dosed in the Phase 3 MAGNITUDE Study of NTLA-2001 as a Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathy (GlobeNewswire)
Mar-09-24 09:45AM	Is Intellia Therapeutics Stock a Buy Now? (Motley Fool)
Mar-06-24 10:35AM	Intellia Therapeutics Stock Has 119% Upside, According to 1 Wall Street Analyst (Motley Fool)
Mar-01-24 01:43PM	Analyst Report: Intellia Therapeutics, Inc. (Morningstar Research)
05:50AM	Loading…
Feb-29-24 05:50AM	A Bull Market Is Here: 2 Magnificent Stocks Down 80% to Buy Right Now (Motley Fool)
Feb-28-24 09:30AM	Intellia Therapeutics, Inc. (NTLA) Crossed Above the 50-Day Moving Average: What That Means for Investors (Zacks) +5.74%
Feb-27-24 11:55AM	Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought (Motley Fool) +12.15%
09:35AM	Intellia Therapeutics, Inc. (NTLA) Just Overtook the 20-Day Moving Average (Zacks)
Feb-23-24 12:22PM	Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q4 2023 Earnings Call Transcript (Insider Monkey)
11:12AM	Intellia (NTLA) Beats on Q4 Earnings, Provides Pipeline Update (Zacks)
09:55AM	Wall Street Analysts See an 185.54% Upside in Intellia Therapeutics, Inc. (NTLA): Can the Stock Really Move This High? (Zacks)
Feb-22-24 10:53PM	Q4 2023 Intellia Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
08:12AM	Intellia Therapeutics Inc (NTLA) Reports Full-Year 2023 Financial Results and Operational Progress (GuruFocus.com)
07:30AM	Intellia Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
Feb-20-24 05:02AM	Cathie Wood Is Betting on This Top Technology: 2 Stocks She Just Bought (Motley Fool)
Feb-17-24 01:59AM	Analysts Say Intellia Therapeutics Stock Could Rise 157% This Year, but Will It Happen? (Motley Fool)
Feb-15-24 10:00AM	Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release (Zacks)
07:30AM	Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis (GlobeNewswire)
06:20AM	Intellia, ReCode partner on genetic medicines for cystic fibrosis (BioPharma Dive)
Feb-14-24 07:30AM	Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2023 Earnings and Company Updates (GlobeNewswire) +6.92%
Feb-13-24 06:05AM	3 Gene Editing Stocks With Unprecedented Surge Potential (InvestorPlace) -10.67%
Feb-10-24 05:09PM	Top 11 CRISPR Stocks To Invest In (Insider Monkey)
Feb-08-24 01:15PM	The 3 Most Undervalued Biotech Stocks to Buy in February 2024 (InvestorPlace) +5.37%
Feb-07-24 11:50AM	Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought (Motley Fool)
Feb-05-24 05:25AM	A Bull Market Is Here: 2 Top Growth Stocks to Buy Hand Over Fist (Motley Fool)
Jan-31-24 05:00PM	Intellia Therapeutics Announces Publication of Positive Interim Phase 1 Data for NTLA-2002 in Patients with Hereditary Angioedema in the New England Journal of Medicine (GlobeNewswire)
12:28PM	3 Once-in-a-Lifetime Gene Editing Stocks with Unprecedented Surge Potential (InvestorPlace)
Jan-30-24 05:10AM	History Says the S&P 500 May Climb in the Triple Digits During This Bull Market. 3 Top Growth Stocks to Buy Before it Does. (Motley Fool) -6.07%
Jan-29-24 09:35AM	Down -19.06% in 4 Weeks, Here's Why Intellia Therapeutics, Inc. (NTLA) Looks Ripe for a Turnaround (Zacks) +6.08%
Jan-27-24 01:25PM	2 Growth Stocks That Could Rocket 144% and 202% Higher This Year, According to Wall Street (Motley Fool)
08:55AM	Is It Too Late to Buy Intellia Therapeutics Stock? (Motley Fool)
Jan-24-24 07:00AM	SparingVision Reaches Final Dose Escalation Step in PRODYGY Trial with SPVN06 for retinitis pigmentosa (GlobeNewswire)
Jan-22-24 05:41PM	3 Biotech Stocks to Turn $10,000 Into $1 Million: January 2024 (InvestorPlace)
Jan-21-24 08:00AM	Better Growth Stock: Intellia Therapeutics vs. CRISPR Therapeutics (Motley Fool)
Jan-18-24 11:50AM	Is it a Good Idea to Invest in Intellia (NTLA) Stock Now? (Zacks)
Jan-13-24 06:05AM	The Top Healthcare Stocks to Buy With $100 (Motley Fool)
Jan-12-24 08:44AM	Is Intellia Therapeutics (NTLA) Stock a Solid Choice Right Now? (Zacks)
Jan-08-24 07:45AM	Better Gene-Editing Stock: Editas Medicine vs. Intellia Therapeutics (Motley Fool) +5.03%
05:52AM	4 Cathie Wood Stocks Wall Street Thinks Will Skyrocket 83% to 168% in 2024 (Motley Fool)
Jan-05-24 10:04AM	Intellia Therapeutics Layoffs 2024: What to Know About the Latest NTLA Job Cuts (InvestorPlace)
Jan-04-24 04:01PM	Intellia Therapeutics Highlights its Three-Year Strategic Priorities and Anticipated 2024 Key Milestones (GlobeNewswire)
12:47PM	Intellia to lay off staff, cut some early research (BioPharma Dive)
Dec-31-23 08:45AM	2 Gene-Editing Stocks That Might Be the Next CRISPR Therapeutics (Motley Fool)
Dec-27-23 06:41PM	13 Most Promising Future Stocks To Buy According To Hedge Funds (Insider Monkey)
Dec-16-23 05:00AM	5 Beaten-Down Stocks That Could Soar in 2024 (Motley Fool)
Dec-13-23 05:20AM	3 Gene-Editing Stocks With the Potential to Mint Millionaires (InvestorPlace) +7.96%
Dec-12-23 06:00AM	Could Intellia Therapeutics Become the Next CRISPR Therapeutics? (Motley Fool)
Dec-10-23 11:57AM	5 Best Genomics Stocks To Buy Now (Insider Monkey)
Nov-28-23 05:30AM	2 Dirt-Cheap Stocks That Could Rocket Higher in a Bull Market (Motley Fool)
Nov-24-23 07:00AM	Gene Editing Will Change Medicineand Maybe Health Investing Too (The Wall Street Journal)
Nov-15-23 11:07AM	Intellia (NTLA) Rises on EC's Orphan Drug Tag for HAE Candidate (Zacks)
Nov-14-23 07:30AM	Intellia Therapeutics Receives European Union Orphan Drug Designation for NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema (GlobeNewswire) +11.09%
Nov-10-23 05:38PM	Analyst Report: Intellia Therapeutics, Inc. (Morningstar Research)
06:30AM	Intellia (NTLA) Beats on Q3 Earnings, Provides Pipeline Update (Zacks)
Nov-09-23 04:06PM	Market Today: Tech Stocks Under Pressure Amid Mixed Earnings and Fed Remarks (GuruFocus.com) -12.27%
03:37PM	3 Biotech Stocks That Are Betting on the Future of Gene Editing (InvestorPlace)
08:29AM	Intellia Therapeutics Inc (NTLA) Reports Q3 2023 Financial Results and Progress in CRISPR Therapies (GuruFocus.com)
07:30AM	Intellia Therapeutics Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
Nov-06-23 08:02AM	Cathie Wood's ARK Innovation Just Had Its Best Week Ever Thanks To Roku, These Huge Winners (Investor's Business Daily)
Nov-02-23 07:00AM	Intellia Presents New Interim Data from the Ongoing Phase 1 Study of NTLA-2001 at the 4th International ATTR Amyloidosis Meeting (GlobeNewswire)
06:45AM	1 Supercharged Growth Stock That Could Make You a Millionaire in 10 Years (Motley Fool)
Oct-30-23 03:46PM	Top 20 Genomics Companies in the World (Insider Monkey)
10:00AM	Beam Therapeutics Inc. (BEAM) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Oct-28-23 07:30AM	Intellia Therapeutics Will Soon Make Biotech History. Is the Stock a Buy? (Motley Fool)
Oct-26-23 10:02AM	Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
07:30AM	Intellia Therapeutics to Present Updated Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis and Hold Conference Call to Discuss Third Quarter 2023 Earnings in November (GlobeNewswire)
Oct-23-23 09:40AM	Intellia (NTLA) Focuses on Developing Gene-Editing Therapies (Zacks)
08:45AM	3 Stocks Cathie Wood Is Buying That Should Be on Your List Too (Motley Fool)
Oct-21-23 05:00AM	Cathie Wood Is Buying These Top Growth Stocks -- and Both Could Make You Richer Over Time (Motley Fool)
Oct-19-23 11:46AM	Intellia's (NTLA) IND for Gene-Editing Therapy Gets FDA Clearance (Zacks)
Oct-18-23 04:10PM	Intellia Stumbles As It Aims For A First-Ever In CRISPR Gene Editing (Investor's Business Daily)
07:00AM	Intellia Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application to Initiate a Pivotal Phase 3 Trial of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis with Cardiomyopathy (GlobeNewswire)
Oct-16-23 12:39PM	Intellia's (NTLA) HAE Candidate Gets EMA's PRIME Designation (Zacks)
10:43AM	16 Best Stocks to Buy and Hold for the Next 15 Years According to Cathie Woods Portfolio (Insider Monkey)

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BASTA JAMES	EVP, General Counsel	Mar 04 '24	Sale	32.99	2,297	75,778	81,571	Mar 05 04:10 PM
Clark Eliana	EVP, Chief Technical Officer	Mar 04 '24	Sale	32.99	605	19,959	71,470	Mar 05 04:10 PM
Sepp-Lorenzino Laura	EVP, Chief Scientific Officer	Jan 08 '24	Sale	28.87	2,275	65,682	43,927	Jan 10 04:15 PM
LEONARD JOHN M	President and CEO	Jan 03 '24	Sale	29.46	19,223	566,310	846,486	Jan 05 04:51 PM
Lebwohl David	EVP, Chief Medical Officer	Jan 03 '24	Sale	29.46	5,843	172,135	54,372	Jan 05 04:50 PM
Sepp-Lorenzino Laura	EVP, Chief Scientific Officer	Jan 03 '24	Sale	29.46	5,532	162,973	46,202	Jan 05 04:50 PM
Goddard Glenn	EVP, Chief Financial Officer	Jan 03 '24	Sale	29.46	5,365	158,053	40,585	Jan 05 04:49 PM
Clark Eliana	EVP, Chief Technical Officer	Jan 03 '24	Sale	29.50	4,608	135,954	40,845	Jan 05 04:44 PM
Hicks Derek	EVP, Chief Business Officer	Jan 03 '24	Sale	29.46	3,877	114,216	36,987	Jan 05 04:46 PM
BASTA JAMES	EVP, General Counsel	Jan 03 '24	Sale	29.46	3,805	112,095	51,474	Jan 05 04:45 PM
Bhanji Muna	Director	Oct 31 '23	Sale	23.90	265	6,334	11,996	Nov 02 04:42 PM
Bhanji Muna	Director	Jul 31 '23	Sale	42.33	265	11,217	12,261	Aug 02 05:19 PM
Bhanji Muna	Director	Jul 06 '23	Sale	39.30	1,867	73,373	12,526	Jul 10 05:21 PM
Clark Eliana	EVP, Chief Technical Officer	Jul 03 '23	Sale	40.51	360	14,584	45,146	Jul 06 03:34 PM
Clark Eliana	EVP, Chief Technical Officer	Jun 20 '23	Option Exercise	12.27	5,000	61,350	50,146	Jun 22 05:52 PM
Clark Eliana	EVP, Chief Technical Officer	Jun 20 '23	Sale	45.00	5,000	225,000	45,146	Jun 22 05:52 PM

Open in Screener

PGNY

Progyny Inc

May 15 • 02:58PM ET

27.13

Dollar change -0.35
Percentage change -1.29	%

Healthcare • Health Information Services • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: VTI VB IJH IWM VXF VBK IWO IJK VTWO VHT

Index	RUT	P/E	44.65	EPS (ttm)	0.61	Insider Own	13.47%	Shs Outstand	95.73M	Perf Week	-15.65%
Market Cap	2.61B	Forward P/E	28.23	EPS next Y	0.96	Insider Trans	-5.04%	Shs Float	83.16M	Perf Month	-18.76%
Income	61.26M	PEG	2.45	EPS next Q	0.17	Inst Own	90.65%	Short Float	8.59%	Perf Quarter	-33.30%
Sales	1.11B	P/S	2.35	EPS this Y	13.87%	Inst Trans	-1.63%	Short Ratio	6.60	Perf Half Y	-10.98%
Book/sh	6.03	P/B	4.50	EPS next Y	36.12%	ROA	8.48%	Short Interest	7.15M	Perf Year	-24.63%
Cash/sh	3.87	P/C	7.01	EPS next 5Y	18.20%	ROE	12.30%	52W Range	23.90 - 44.95	Perf YTD	-27.04%
Dividend Est.	-	P/FCF	13.70	EPS past 5Y	-	ROI	10.41%	52W High	-39.65%	Beta	1.47
Dividend TTM	-	Quick Ratio	3.31	Sales past 5Y	61.75%	Gross Margin	21.89%	52W Low	13.50%	ATR (14)	1.48
Dividend Ex-Date	-	Current Ratio	3.31	EPS Y/Y TTM	38.12%	Oper. Margin	5.93%	RSI (14)	24.39	Volatility	6.37% 3.72%
Employees	566	Debt/Eq	0.03	Sales Y/Y TTM	26.94%	Profit Margin	5.53%	Recom	1.30	Target Price	39.00
Option/Short	Yes / Yes	LT Debt/Eq	0.03	EPS Q/Q	-5.27%	Payout	0.00%	Rel Volume	0.79	Prev Close	27.48
Sales Surprise	-3.91%	EPS Surprise	28.50%	Sales Q/Q	7.62%	Earnings	May 09 AMC	Avg Volume	1.08M	Price	27.13
SMA20	-14.31%	SMA50	-20.50%	SMA200	-23.71%	Trades		Volume	724,327	Change	-1.29%

Date	Action	Analyst	Rating Change	Price Target Change
May-10-24	Downgrade	KeyBanc Capital Markets	Overweight → Sector Weight
Feb-26-24	Initiated	Leerink Partners	Outperform	$49
Jan-03-24	Initiated	Barclays	Overweight	$48
Sep-27-23	Initiated	Canaccord Genuity	Buy	$46
May-22-23	Initiated	BTIG Research	Buy	$50
Apr-21-23	Initiated	Cantor Fitzgerald	Overweight	$44
Jan-05-23	Downgrade	SVB Leerink	Outperform → Mkt Perform	$34
Sep-16-22	Initiated	KeyBanc Capital Markets	Overweight	$55
Sep-07-22	Initiated	Truist	Buy	$56
Dec-02-21	Initiated	Jefferies	Buy	$60
Nov-22-21	Downgrade	Citigroup	Buy → Neutral	$60 → $64
Sep-30-21	Initiated	Berenberg	Buy	$81
Aug-12-21	Initiated	Barclays	Overweight	$64
Jun-02-21	Downgrade	Guggenheim	Buy → Neutral
Apr-29-21	Resumed	JP Morgan	Overweight	$65
Mar-10-21	Upgrade	BofA Securities	Neutral → Buy	$53
Jul-01-20	Initiated	SVB Leerink	Outperform	$35
Jun-02-20	Initiated	Guggenheim	Buy	$30
Nov-19-19	Initiated	SVB Leerink	Outperform	$28
Nov-19-19	Initiated	Piper Jaffray	Overweight	$33

Show Previous Ratings

May-14-24 11:00AM	Progyny, Inc. to Present at BofA Securities 2024 Healthcare Conference and Leerink Partners Healthcare Crossroads Conference 2024 (GlobeNewswire)
May-10-24 03:24PM	Progyny, Inc. (NASDAQ:PGNY) Q1 2024 Earnings Call Transcript (Insider Monkey) -15.29%
02:01PM	Top Midday Decliners (MT Newswires)
01:20PM	Progyny Inc (PGNY) Q1 2024 Earnings: Mixed Results Amid Market Challenges (GuruFocus.com)
11:26AM	Progyny Shares Drop After Q1 Revenue Miss, KeyBanc Downgrade (MT Newswires)
11:07AM	Loading…
11:07AM	RBC Capital Just Raised Its Price Target on Sweetgreen (SG) Stock (InvestorPlace)
08:53AM	Why Is Progyny (PGNY) Stock Down 27% Today? (InvestorPlace)
07:30AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace)
06:16AM	KeyBanc Downgrades Progyny to Sector Weight From Overweight, Cites Questions on Visibility, 'Potential Further Headwinds' (MT Newswires)
May-09-24 08:57PM	PGNY Stock Earnings: Progyny Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
04:38PM	Progyny Q1 Adjusted Earnings, Revenue Rise -- Shares Plummet After Hour (MT Newswires)
04:32PM	Progyny: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Progyny, Inc. Announces First Quarter 2024 Results (GlobeNewswire)
May-03-24 02:48AM	Insider Sale: President Michael Sturmer Sells Shares of Progyny Inc (PGNY) (GuruFocus.com)
Apr-25-24 02:00PM	Progyny, Inc. Announces Details for Its First Quarter 2024 Results Report (GlobeNewswire)
09:23AM	Loading…
Apr-17-24 09:23AM	Progyny and Fertility Matters Canada Recognize Canadian Fertility Awareness Week to Advocate for Expanded Access to Family Building Care (GlobeNewswire)
Apr-13-24 12:18PM	Jim Cramer's 10 Favorite Healthcare Stock Picks in 2024 (Insider Monkey)
Apr-04-24 08:59AM	Progyny and RESOLVE to Honor National Infertility Awareness Week with Events Spanning Coast to Coast (GlobeNewswire)
Apr-03-24 07:01PM	Insider Sell: President Michael Sturmer Sells Shares of Progyny Inc (PGNY) (GuruFocus.com)
Mar-30-24 01:30AM	Executive Chairman David Schlanger Sells 71,272 Shares of Progyny Inc (PGNY) (GuruFocus.com)
Mar-28-24 08:13AM	Insiders Are Dumping These 10 Healthcare Stocks (Insider Monkey)
01:37AM	Executive Chairman David Schlanger Sells Shares of Progyny Inc (PGNY) (GuruFocus.com)
Mar-26-24 07:49AM	20 Highest Paid CEOs in the US and Their College Degrees (Insider Monkey)
Mar-18-24 12:00PM	Progyny, Inc. to Present at KeyBanc Life Sciences & MedTech Investor Forum (GlobeNewswire)
Mar-13-24 04:30PM	The 7 Most Undervalued Mid-Cap Stocks to Buy in March 2024 (InvestorPlace)
Mar-11-24 12:00PM	Progyny, Inc. to Present at Barclays 26th Annual Global Healthcare Conference (GlobeNewswire)
Feb-29-24 05:48PM	IVF Is Increasingly Big Business. Alabamas Ruling Could Actually Make It Bigger. (Barrons.com) +5.40%
07:30AM	Progyny, Inc. Announces Share Repurchase Program (GlobeNewswire)
Feb-28-24 10:41AM	Progyny Stock Falls Sharply After Earnings. What the IVF Ruling Means for It. (Barrons.com) -15.05%
10:15AM	Progyny, Inc. (NASDAQ:PGNY) Q4 2023 Earnings Call Transcript (Insider Monkey)
09:01AM	Loading…
09:01AM	Progyny Stock Is Falling After Earnings. What the IVF Ruling Means for It. (Barrons.com)
07:19AM	Q4 2023 Progyny Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-27-24 05:11PM	Progyny: Q4 Earnings Snapshot (Associated Press Finance)
04:34PM	Progyny Inc (PGNY) Surpasses $1 Billion Annual Revenue, Net Income Soars in Q4 (GuruFocus.com)
04:01PM	Progyny, Inc. Announces Fourth Quarter 2023 Results (GlobeNewswire)
Feb-13-24 04:30PM	Progyny, Inc. Announces Details for Its Fourth Quarter and Full Year 2023 Results Report (GlobeNewswire)
Feb-08-24 03:06AM	Executive Chairman David Schlanger Sells 20,000 Shares of Progyny Inc (PGNY) (GuruFocus.com)
Feb-05-24 11:30PM	Executive Chairman David Schlanger Sells 60,000 Shares of Progyny Inc (PGNY) (GuruFocus.com)
Jan-24-24 01:36PM	3 Cash-Rich Stocks to Buy for Peace of MInd in 2024 (InvestorPlace)
Jan-17-24 09:30AM	Vistia Health selects Progyny as its preferred fertility and family building benefits provider (PR Newswire)
Jan-16-24 06:10PM	3 Mid-Cap Stocks Poised for a Breakout in 2024 (InvestorPlace)
Jan-12-24 09:23AM	16 Best Mid-Cap Growth Stocks To Buy Now (Insider Monkey)
05:03AM	Executive Chairman David Schlanger Sells 66,002 Shares of Progyny Inc (GuruFocus.com)
Jan-11-24 09:01AM	Progyny Expands its Leadership Team (GlobeNewswire)
Jan-08-24 10:30AM	Progyny, Inc. to Present at 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-06-24 03:12AM	Progyny Inc CFO Mark Livingston Sells 12,368 Shares (GuruFocus.com)
Jan-05-24 03:02AM	Executive Chairman David Schlanger Sells 13,998 Shares of Progyny Inc (PGNY) (GuruFocus.com)
Dec-29-23 09:01PM	Progyny Inc Executive Chairman David Schlanger Sells 156,031 Shares (GuruFocus.com)
Dec-24-23 03:01AM	Executive Chairman David Schlanger Sells 162,906 Shares of Progyny Inc (PGNY) (GuruFocus.com)
Dec-19-23 06:49AM	24 Countries With Biggest Population Decline (Insider Monkey) +5.33%
05:10AM	4 Unstoppable Multibaggers to Buy in 2024 and Hold for the Next Decade (Motley Fool)
Nov-20-23 10:17AM	Does Progyny (PGNY) have a Long Runway for Growth? (Insider Monkey)
Nov-13-23 12:45PM	Progyny (PGNY) is an Incredible Growth Stock: 3 Reasons Why (Zacks)
Nov-10-23 12:00PM	Progyny, Inc. to Present at Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum (GlobeNewswire)
Nov-09-23 03:52PM	Progyny, Inc. (NASDAQ:PGNY) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-07-23 05:58PM	Progyny: Q3 Earnings Snapshot (Associated Press Finance)
04:49PM	Progyny Inc (PGNY) Posts Record Revenue in Q3 2023, Raises Full-Year Guidance (GuruFocus.com)
04:05PM	Progyny, Inc. Announces Third Quarter 2023 Results (GlobeNewswire)
Nov-02-23 06:04AM	The Stage Is Set for a Rally: Canaccord Sees up to 290% Upside for These 3 Stocks (TipRanks)
Nov-01-23 11:27PM	30 Most Fertile Countries in the World Heading into 2024 (Insider Monkey)
10:01AM	Earnings Preview: Charles River Laboratories (CRL) Q3 Earnings Expected to Decline (Zacks)
09:00AM	The Broken Brown Egg and Progyny Launch 2023 Awareness, Hope, and Activism Grant to Help BIPOC Individuals and Couples Expand Their Families (GlobeNewswire)
Oct-31-23 10:01AM	Earnings Preview: Progyny (PGNY) Q3 Earnings Expected to Decline (Zacks)
Oct-27-23 09:45AM	2 Super Stocks That Could Go Parabolic (Motley Fool)
Oct-24-23 02:00PM	Progyny, Inc. Announces Details for Its Third Quarter 2023 Results Report (GlobeNewswire)
Oct-10-23 11:34AM	Small Growth Stocks Have Gotten Crushed. Time to Buy. (Barrons.com)
Sep-27-23 10:16AM	3 Growth Stocks to Buy That Could Be Massive Long-Term Winners (Motley Fool)
Sep-26-23 07:35PM	Progyny (PGNY): Unveiling Its True Value (GuruFocus.com)
Sep-01-23 12:45PM	3 Reasons Growth Investors Will Love Progyny (PGNY) (Zacks)
Aug-29-23 10:46AM	Wall Street Loves These 3 Growth Stocks; Should You? (Motley Fool)
Aug-22-23 11:56AM	Progyny Celebrates More Than 30,000 Amazonians Supported on Their Family Building Journeys (GlobeNewswire)
Aug-16-23 12:45PM	Here is Why Growth Investors Should Buy Progyny (PGNY) Now (Zacks)
07:57AM	Heres Why Progyny (PGNY) Outperformed in Q2 (Insider Monkey)
Aug-11-23 12:00PM	Progyny (PGNY) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Aug-10-23 06:28AM	TPG GP A, LLC Reduces Stake in Progyny Inc (GuruFocus.com)
Aug-07-23 08:29AM	Fertility benefits management company Progyny expands to offer menopause care (American City Business Journals)
Aug-05-23 09:24AM	Is There Now An Opportunity In Progyny, Inc. (NASDAQ:PGNY)? (Simply Wall St.)
Aug-04-23 09:01AM	Progyny Unveils Nationwide Access to Menopause Care (GlobeNewswire) +6.11%
06:47AM	Q2 2023 Progyny Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-03-23 09:00PM	Compared to Estimates, Progyny (PGNY) Q2 Earnings: A Look at Key Metrics (Zacks)
05:35PM	Progyny (PGNY) Beats Q2 Earnings and Revenue Estimates (Zacks)
04:28PM	Progyny: Q2 Earnings Snapshot (AP Finance)
04:01PM	Progyny, Inc. Announces Second Quarter 2023 Results (GlobeNewswire)
Jul-21-23 11:20AM	In their rush to offer fertility benefits, employers could be unwittingly creating a new inequity for LGTBQIA+ employees (Fortune)
Jul-20-23 12:00PM	Progyny, Inc. Announces Details for Its Second Quarter 2023 Results Report (GlobeNewswire)
10:29AM	Strength Seen in Harrow (HROW): Can Its 17.8% Jump Turn into More Strength? (Zacks)
Jul-18-23 11:40AM	MD vs. PGNY: Which Stock Is the Better Value Option? (Zacks)
06:37AM	Progyny (NASDAQ:PGNY) grows 4.8% this week, taking three-year gains to 54% (Simply Wall St.)
Jul-17-23 06:51PM	7 Growth Stocks to Buy to go Beyond the Magnificent 7 (InvestorPlace)
04:37AM	30 Countries With Highest Rates of Population Growth (Insider Monkey)
Jul-11-23 03:00PM	Small Growth Stocks Are Finally Catching Big Tech (Barrons.com)
Jul-10-23 10:00AM	4 Top Stocks to Buy in July and Hold Forever (Motley Fool)
Jul-07-23 12:00PM	What Makes Progyny (PGNY) a New Buy Stock (Zacks)
Jun-29-23 08:30AM	Quantum Health Partners With Progyny To Launch New Family-Building Benefits Offering (Business Wire)
Jun-27-23 01:26PM	Progyny (NASDAQ:PGNY) Is Experiencing Growth In Returns On Capital (Simply Wall St.)
Jun-21-23 08:00PM	PGNY: Lowering target price to $50.00 (Argus Research)
Jun-15-23 09:30AM	These 3 Unique Stocks Have Undeniable Long-Term Upside (Motley Fool)
Jun-14-23 10:02AM	The Best Stocks to Invest $10,000 in Right Now (Motley Fool)
Jun-12-23 09:55AM	Should You Buy Progyny (PGNY) After Golden Cross? (Zacks)
Jun-07-23 07:06AM	Progyny, Inc.'s (NASDAQ:PGNY) Intrinsic Value Is Potentially 99% Above Its Share Price (Simply Wall St.)

Progyny, Inc. is a fertility benefits management company. It provides fertility solutions to employers, managing IUI, in vitro fertilization (IVF), egg freezing, and other fertility treatments. It operates through one segment: fertility and pharmacy benefits solutions. It also delivers treatment services and access to the firm's network of fertility specialist. The company was founded on April 3, 2008 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Payson Norman	Director	Nov 23 '24	Sale	56.29	200	11,258	580,656	Nov 26 04:34 PM
Sturmer Michael E	PRESIDENT	May 01 '24	Sale	31.95	4,515	144,254	380,038	May 02 07:05 PM
Livingston Mark S.	CHIEF FINANCIAL OFFICER	Apr 01 '24	Option Exercise	3.95	20,627	81,477	72,875	Apr 03 05:16 PM
Schlanger David J	Executive Chairman	Apr 01 '24	Option Exercise	3.95	1,000	3,950	87,312	Apr 03 05:27 PM
Livingston Mark S.	CHIEF FINANCIAL OFFICER	Apr 01 '24	Sale	37.62	11,165	419,979	50,119	Apr 03 05:16 PM
Sturmer Michael E	PRESIDENT	Apr 01 '24	Sale	37.60	6,395	240,452	384,553	Apr 03 05:23 PM
Schlanger David J	Executive Chairman	Apr 01 '24	Sale	37.52	1,000	37,522	83,631	Apr 03 05:27 PM
Schlanger David J	Executive Chairman	Mar 27 '24	Option Exercise	3.95	71,272	281,845	157,584	Mar 29 07:01 PM
Schlanger David J	Executive Chairman	Mar 27 '24	Sale	37.80	71,272	2,694,267	86,312	Mar 29 07:01 PM
Schlanger David J	Executive Chairman	Mar 26 '24	Option Exercise	3.95	305	1,206	86,617	Mar 27 05:49 PM
Schlanger David J	Executive Chairman	Mar 26 '24	Sale	37.50	305	11,439	86,312	Mar 27 05:49 PM
Schlanger David J	Executive Chairman	Mar 25 '24	Option Exercise	3.95	2,597	10,270	88,909	Mar 27 05:49 PM
Schlanger David J	Executive Chairman	Mar 25 '24	Sale	37.65	2,597	97,778	86,312	Mar 27 05:49 PM
Schlanger David J	Executive Chairman	Mar 21 '24	Option Exercise	3.95	5,826	23,039	92,138	Mar 25 06:42 PM
Schlanger David J	Executive Chairman	Mar 21 '24	Sale	37.74	5,826	219,877	86,312	Mar 25 06:42 PM
Livingston Mark S.	CHIEF FINANCIAL OFFICER	Mar 01 '24	Option Exercise	3.95	22,000	86,900	65,647	Mar 05 05:04 PM
Livingston Mark S.	CHIEF FINANCIAL OFFICER	Mar 01 '24	Sale	36.64	12,610	461,977	38,254	Mar 05 05:04 PM
Sturmer Michael E	PRESIDENT	Mar 01 '24	Sale	36.63	11,009	403,260	141,738	Mar 05 04:57 PM
Sturmer Michael E	PRESIDENT	Feb 06 '24	Sale	40.00	2,260	90,400	158,532	Feb 08 06:53 PM
Schlanger David J	Executive Chairman	Feb 05 '24	Option Exercise	3.95	20,000	79,090	106,312	Feb 07 06:38 PM
Schlanger David J	Executive Chairman	Feb 05 '24	Sale	38.50	20,000	769,928	86,312	Feb 07 06:38 PM
Schlanger David J	Executive Chairman	Feb 02 '24	Option Exercise	3.95	30,000	118,635	116,312	Feb 05 06:51 PM
Schlanger David J	Executive Chairman	Feb 02 '24	Sale	38.92	30,000	1,167,490	86,312	Feb 05 06:51 PM
Schlanger David J	Executive Chairman	Feb 01 '24	Option Exercise	3.95	30,000	118,635	116,312	Feb 05 06:51 PM
Livingston Mark S.	CHIEF FINANCIAL OFFICER	Feb 01 '24	Option Exercise	3.95	22,000	86,900	68,871	Feb 05 07:03 PM
Schlanger David J	Executive Chairman	Feb 01 '24	Sale	38.29	30,000	1,148,635	86,312	Feb 05 06:51 PM
Livingston Mark S.	CHIEF FINANCIAL OFFICER	Feb 01 '24	Sale	37.84	12,651	478,767	43,871	Feb 05 07:03 PM
Sturmer Michael E	PRESIDENT	Feb 01 '24	Sale	37.89	6,395	242,307	160,792	Feb 05 06:57 PM
Schlanger David J	Executive Chairman	Jan 08 '24	Option Exercise	3.95	66,002	261,005	152,314	Jan 10 06:31 PM
Schlanger David J	Executive Chairman	Jan 08 '24	Sale	37.88	66,002	2,500,156	86,312	Jan 10 06:31 PM
Livingston Mark S.	CHIEF FINANCIAL OFFICER	Jan 02 '24	Option Exercise	3.95	22,000	86,900	71,871	Jan 05 06:01 AM
Schlanger David J	Executive Chairman	Jan 02 '24	Option Exercise	3.95	13,998	55,355	102,437	Jan 04 06:30 PM
Schlanger David J	Executive Chairman	Jan 02 '24	Sale	37.58	13,998	526,024	88,439	Jan 04 06:30 PM
Livingston Mark S.	CHIEF FINANCIAL OFFICER	Jan 02 '24	Sale	36.59	12,368	452,540	46,871	Jan 05 06:01 AM
Sturmer Michael E	PRESIDENT	Jan 02 '24	Sale	36.81	6,395	235,400	167,187	Jan 04 06:42 PM
Schlanger David J	Executive Chairman	Dec 27 '23	Option Exercise	3.95	76,031	300,665	164,470	Dec 28 08:19 PM
Schlanger David J	Executive Chairman	Dec 27 '23	Sale	37.66	76,031	2,863,525	88,439	Dec 28 08:19 PM
Schlanger David J	Executive Chairman	Dec 26 '23	Option Exercise	3.95	80,000	316,360	168,439	Dec 28 08:19 PM
Schlanger David J	Executive Chairman	Dec 26 '23	Sale	37.93	80,000	3,034,760	88,439	Dec 28 08:19 PM
Schlanger David J	Executive Chairman	Dec 22 '23	Option Exercise	3.95	80,000	316,360	168,439	Dec 22 04:40 PM
Schlanger David J	Executive Chairman	Dec 22 '23	Sale	38.11	80,000	3,048,408	88,439	Dec 22 04:40 PM
Schlanger David J	Executive Chairman	Dec 21 '23	Option Exercise	3.95	80,000	316,360	168,439	Dec 22 04:40 PM
Schlanger David J	Executive Chairman	Dec 21 '23	Sale	37.65	80,000	3,011,952	88,439	Dec 22 04:40 PM
Schlanger David J	Executive Chairman	Dec 20 '23	Option Exercise	3.95	2,906	11,492	91,345	Dec 22 04:40 PM
Schlanger David J	Executive Chairman	Dec 20 '23	Sale	37.50	2,906	108,987	88,439	Dec 22 04:40 PM
Schlanger David J	Executive Chairman	Dec 14 '23	Option Exercise	3.95	1,063	4,204	89,502	Dec 18 07:39 PM
Schlanger David J	Executive Chairman	Dec 14 '23	Sale	37.53	1,063	39,894	88,439	Dec 18 07:39 PM
GORDON KEVIN K	Director	Dec 11 '23	Sale	35.93	2,500	89,825	9,854	Dec 13 07:06 PM
Livingston Mark S.	CHIEF FINANCIAL OFFICER	Dec 01 '23	Option Exercise	3.95	44,000	173,800	102,377	Dec 05 07:44 PM
Livingston Mark S.	CHIEF FINANCIAL OFFICER	Dec 01 '23	Sale	34.62	25,087	868,512	49,983	Dec 05 07:44 PM
Sturmer Michael E	PRESIDENT	Dec 01 '23	Sale	34.13	12,696	433,314	173,806	Dec 05 07:49 PM
TPG GP A, LLC	Former 10% Owner	Aug 07 '23	Sale	41.08	2,900,000	119,132,000	6,350,000	Aug 09 04:42 PM
Anevski Peter	CHIEF EXECUTIVE OFFICER	Jul 14 '23	Option Exercise	3.95	17,990	71,060	225,937	Jul 18 04:27 PM
Anevski Peter	CHIEF EXECUTIVE OFFICER	Jul 14 '23	Sale	38.95	17,990	700,710	207,947	Jul 18 04:27 PM
Anevski Peter	CHIEF EXECUTIVE OFFICER	Jul 14 '23	Sale	38.95	2,096	81,639	1	Jul 18 04:27 PM
Anevski Peter	CHIEF EXECUTIVE OFFICER	Jul 13 '23	Option Exercise	3.95	32,000	126,400	239,947	Jul 14 04:01 PM
Schlanger David J	Executive Chairman	Jul 13 '23	Option Exercise	0.91	67,457	61,386	138,263	Jul 14 04:02 PM
Schlanger David J	Executive Chairman	Jul 13 '23	Sale	38.95	67,457	2,627,450	70,806	Jul 14 04:02 PM
Anevski Peter	CHIEF EXECUTIVE OFFICER	Jul 13 '23	Sale	38.94	32,000	1,246,080	207,947	Jul 14 04:01 PM
Anevski Peter	CHIEF EXECUTIVE OFFICER	Jul 13 '23	Sale	38.94	8,000	311,520	2,097	Jul 14 04:01 PM
Anevski Peter	CHIEF EXECUTIVE OFFICER	Jul 12 '23	Option Exercise	3.95	23,572	93,109	231,519	Jul 14 04:01 PM
Schlanger David J	Executive Chairman	Jul 12 '23	Option Exercise	0.91	38,687	35,205	109,493	Jul 14 04:02 PM
Schlanger David J	Executive Chairman	Jul 12 '23	Sale	38.64	38,687	1,494,866	70,806	Jul 14 04:02 PM
Anevski Peter	CHIEF EXECUTIVE OFFICER	Jul 12 '23	Sale	38.64	23,572	910,822	207,947	Jul 14 04:01 PM
Anevski Peter	CHIEF EXECUTIVE OFFICER	Jul 12 '23	Sale	38.64	4,890	188,950	10,097	Jul 14 04:01 PM
Anevski Peter	CHIEF EXECUTIVE OFFICER	Jul 03 '23	Option Exercise	3.95	6,439	25,434	222,363	Jul 06 04:01 PM
Schlanger David J	Executive Chairman	Jul 03 '23	Option Exercise	0.91	18,856	17,159	92,343	Jul 06 04:02 PM
Schlanger David J	Executive Chairman	Jul 03 '23	Sale	38.76	18,856	730,859	73,487	Jul 06 04:02 PM
Anevski Peter	CHIEF EXECUTIVE OFFICER	Jul 03 '23	Sale	38.78	6,439	249,704	215,924	Jul 06 04:01 PM
Anevski Peter	CHIEF EXECUTIVE OFFICER	Jul 03 '23	Sale	38.78	1,610	62,436	14,987	Jul 06 04:01 PM
Scott Cheryl	Director	Jun 27 '23	Sale	37.27	1,170	43,606	9,744	Jul 07 05:15 PM
Anevski Peter	CHIEF EXECUTIVE OFFICER	Jun 07 '23	Option Exercise	3.95	16,000	63,200	231,924	Jun 08 08:00 PM
Anevski Peter	CHIEF EXECUTIVE OFFICER	Jun 07 '23	Sale	40.97	16,000	655,512	215,924	Jun 08 08:00 PM
Anevski Peter	CHIEF EXECUTIVE OFFICER	Jun 07 '23	Sale	40.97	4,000	163,878	16,597	Jun 08 08:00 PM
Anevski Peter	CHIEF EXECUTIVE OFFICER	Jun 06 '23	Option Exercise	3.95	16,000	63,200	231,924	Jun 07 06:22 PM
Anevski Peter	CHIEF EXECUTIVE OFFICER	Jun 06 '23	Sale	41.01	16,000	656,086	215,924	Jun 07 06:22 PM
Anevski Peter	CHIEF EXECUTIVE OFFICER	Jun 06 '23	Sale	41.01	4,000	164,021	20,597	Jun 07 06:22 PM
Anevski Peter	CHIEF EXECUTIVE OFFICER	Jun 05 '23	Option Exercise	3.95	16,000	63,200	231,924	Jun 07 06:22 PM
Schlanger David J	Executive Chairman	Jun 05 '23	Option Exercise	0.91	41,666	37,916	115,153	Jun 07 06:23 PM
Schlanger David J	Executive Chairman	Jun 05 '23	Sale	40.00	41,666	1,666,824	73,487	Jun 07 06:23 PM
Anevski Peter	CHIEF EXECUTIVE OFFICER	Jun 05 '23	Sale	40.00	16,000	640,057	215,924	Jun 07 06:22 PM
Anevski Peter	CHIEF EXECUTIVE OFFICER	Jun 05 '23	Sale	40.00	4,000	160,014	24,597	Jun 07 06:22 PM
Anevski Peter	CHIEF EXECUTIVE OFFICER	Jun 02 '23	Option Exercise	3.95	16,000	63,200	231,924	Jun 05 05:08 PM
Schlanger David J	Executive Chairman	Jun 02 '23	Option Exercise	0.91	41,667	37,917	115,154	Jun 05 04:48 PM
Schlanger David J	Executive Chairman	Jun 02 '23	Sale	38.68	41,667	1,611,680	73,487	Jun 05 04:48 PM
Anevski Peter	CHIEF EXECUTIVE OFFICER	Jun 02 '23	Sale	38.67	16,000	618,720	215,924	Jun 05 05:08 PM
Anevski Peter	CHIEF EXECUTIVE OFFICER	Jun 02 '23	Sale	38.67	4,000	154,680	28,597	Jun 05 05:08 PM
Anevski Peter	CHIEF EXECUTIVE OFFICER	Jun 01 '23	Option Exercise	3.95	16,000	63,200	231,924	Jun 05 05:08 PM
Schlanger David J	Executive Chairman	Jun 01 '23	Option Exercise	0.91	41,667	37,917	115,154	Jun 05 04:48 PM
Schlanger David J	Executive Chairman	Jun 01 '23	Sale	37.55	41,667	1,564,431	73,487	Jun 05 04:48 PM
Anevski Peter	CHIEF EXECUTIVE OFFICER	Jun 01 '23	Sale	37.55	16,000	600,850	215,924	Jun 05 05:08 PM
Anevski Peter	CHIEF EXECUTIVE OFFICER	Jun 01 '23	Sale	37.55	4,000	150,212	32,597	Jun 05 05:08 PM
GORDON KEVIN K	Director	May 24 '23	Sale	38.24	1,410	53,918	12,354	May 26 05:03 PM
Anevski Peter	CHIEF EXECUTIVE OFFICER	May 16 '23	Option Exercise	3.95	4,608	18,202	220,532	May 18 07:21 PM
Anevski Peter	CHIEF EXECUTIVE OFFICER	May 16 '23	Sale	35.94	4,608	165,612	215,924	May 18 07:21 PM
Anevski Peter	CHIEF EXECUTIVE OFFICER	May 16 '23	Sale	35.94	1,153	41,439	36,597	May 18 07:21 PM

affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings

KYTX

Kyverna Therapeutics Inc.

URGN

UroGen Pharma Ltd

CDNA

Caredx Inc

NTLA

Intellia Therapeutics Inc

PGNY

Progyny Inc

Upgrade your FINVIZ experience